Stocks · News reference

Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48

Sep 24, 2026, 12:27 PMBenzinga Newsdesk

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $50 to $48.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 25, 2026, 9:01 PMBenzinga Newsdesk
FDA Classifies Boston Scientific's Recall Of Imager II Angiographic Catheters As Class I Due To Potential Catheter Tip Degradation And Detachment Risk
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/angiographic-catheter-recall-boston-scientific-removes-imager-ii-angiographic-catheters
BSX
Globenewswire IncSep 24, 2026, 9:54 AMResearchandmarkets.Com
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig
ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.
ABT MDT BSX
SEC EDGARSep 23, 2026, 10:01 AMSEC EDGAR
8-K filing — BOSTON SCIENTIFIC CORP (BSX)
Filed: 2026-09-23 AccNo: 0000885725-26-000061 Size: 180 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
BSX